Maternal and child outcomes after pregnancy-associated and postpartum cancer

Project number: 
19-026
Approval date: 
Thursday, May 9, 2019
Principal Investigator: 
Metcalfe,Amy
Institution: 
University of Calgary (U of C)
Funding Agency: 
Canadian Institutes of Health Research(CIHR),Canadian Institutes of Health Research(CIHR)
Datasets requested: 
bc cancer-external
bc cancer
Medical Services Plan (BC Ministry of Health)
Consolidation file (BC Ministry of Health)
Perinatal Services BC
Births (BC Vital Statistics Agency)
Consolidation - demographic (Ministry of Health)
NACRS
Deaths (BC Vital Statistics Agency)
Hospital Separations (BC Ministry of Health)
consolidation - census geocodes
Research objective: 

Objective 1: To determine survival and cancer recurrence rates in women diagnosed with cancer during pregnancy or within 365 days after delivery.
Hypothesis 1: Survival rates in women diagnosed with cancer during pregnancy or within 365 days after delivery will be lower than survival rates in women diagnosed with cancer 3 - 5 years before pregnancy. Recurrence rates in women diagnosed with cancer during pregnancy or within 365 days after delivery will be higher than recurrence rates in women diagnosed with cancer 3 - 5 years before pregnancy.

Objective 2: To assess whether induced abortion is associated with greater survival following a diagnosis of cancer within pregnancy, up to 20 weeks gestation.
Hypothesis 2: Induced abortion following a diagnosis of cancer within pregnancy, up to 20 weeks' gestation, will be associated with greater survival when compared to no induced abortion following a diagnosis of cancer within pregnancy.

Objective 3: To evaluate the health status of children born to women with cancer who were, or were not, treated with chemotherapy during pregnancy, each compared to a) children who were not exposed to cancer in utero and b) its sibling born when the mother did not have cancer (unexposed).
Hypothesis 3: Children born to women with cancer who were treated with chemotherapy during pregnancy will have lower health status than those children born to women with cancer who were not treated with chemotherapy during pregnancy.

Objective 4: Among pregnant women with cancer (with or without chemotherapy), to estimate the proportion of adverse child health outcomes that can be attributed to the cancer, treatment with chemotherapy, and provider-initiated preterm birth.
Hypothesis 4: The proportion of adverse child health outcomes that can be attributed to provider-initiated preterm birth is less than than the proportion attributable to in utero exposure to cancer in a pregnancy brought to term.

Objective 5: To determine whether the time interval between a pre-pregnancy diagnosis of cancer and estimated date of conception is associated with risk of adverse obstetrical and perinatal outcomes.
Hypothesis 5: There is an optimal time interval between a pre-pregnancy diagnosis of cancer and a subsequent pregnancy to minimize the risk of adverse obstetrical and perinatal outcomes.


Page last revised: September 2, 2019